Agila chief among highest-paid execs in India; J&J to pay $600K in first hip implant settlements;

 @FiercePharma: TNF inhibitors-Enbrel, Remicade, Humira, etc.--may actually lower heart attack risks in psoriasis patients. More | Follow @FiercePharma

> India's Agila Specialties, a unit of Strides Arcolab said to be on the block, paid its CEO enough last year to put him among the highest-paid executives in India. Report

> Johnson & Johnson ($JNJ) agreed to pay about $600,000 to settle three cases over hip implants recalled in 2010, the first among thousands of patient lawsuits it faces. Report

> Pfizer ($PFE) has to sort out a host of manufacturing questions as it prepares to spin off the animal health unit Zoetis, including which Pfizer sites will continue to turn out the unit's products. Report

> Johnson & Johnson CEO William Weldon will serve on the JPMorgan Chase committee investigating the derivative trades that spawned $5.8 billion in losses this year. Report

> Researchers advised the WHO to review a drug used to prevent life-threatening bleeding in childbirth, saying there's not enough evidence that it's effective. Report

> Watson Pharmaceuticals ($WPI) launched a knockoff version of Sunovion Pharmaceuticals' bronchospasm remedy Xopenex. Report

Medical Device News

@FierceMedDev: More trouble for St. Jude as study questions safety of Durata leads. Report | Follow @FierceMedDev

 @MarkHFierce: GE is among three investors who committed $20 million to Ornim, a maker of a non invasive blood flow/oxygen monitor. Release | Follow @MarkHFierce

 @DamianFierce: Maine's medical device middlemen fret over how impending 2.3% tax will cut into profits. More | Follow @DamianFierce

> General Electric invests in Israeli maker of blood monitoring device. News

> Medtronic posts 5% income boost despite CRM dip in Q1. More

> Discontinued St. Jude catheter finds new life at Vascular Solutions. Item

Biotech News

 @FierceBiotech: MediciNova snags $20M deal to finance R&D work. Item | Follow @FierceBiotech

 @JohnCFierce: Kineta uses unorthodox strategy to push autoimmune drug into clinic--my take on an unusual approach to drug development. Editor's Corner | Follow @JohnCFierce

 @RyanMFierce: Closer to mainstream media, Fast Company mag caught up with Sanofi's social strategy for diabetes. More | Follow @RyanMFierce

> Controversial stem cell treatment put to test in groundbreaking autism study. Article

> Buzz: Genomics startup Halcyon Molecular tanks. More

> FDA pushes back PDUFA date on crucial Pfizer app for tofacitinib. Story

> Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline. News

Pharma Manufacturing News

> Roche CEO says Genentech has resolved Perjeta production problems. Story

> $19M Cambrex plant expansion to benefit manufacturer and local community. News

> GSK closes 50-year-old India plant, 'retires' 330. Report

> API growth to spurt in Central, South America. More

Biotech Research News

> Old antifungal drug also fights tumors, researchers discover. Article

> Scientists discover wound-healing secret. Story

> A cool $1M to fund preclinical work on nanotech/siRNA cancer drug. More

> Dana-Farber, Broad Institute spot CYCLOPS gene class in cancer fight. New

And Finally... Newer psoriasis drugs may lower heart attack risks for patients. Report